GSK’s Blenrep combinations approved in Singapore for relapsed or refractory multiple myeloma
GSK’s Blenrep combinations approved in Singapore for relapsed or refractory multiple myeloma August 21, 2026 | Friday |…
New launches, innovative portfolio set to drive gains for GSK Pharma stock | Markets News
In addition to a strong Q1 show, brokerages expect the company to post strong growth in…
GSK India aims to double revenue to ₹8K cr by FY30: MD Bhushan Akshikar | Industry News
Oncology currently makes a negligible contribution to GSK India’s revenue. How materially can it contribute over…
GSK’s Blenrep Gets Chinese Regulatory Nod Amid Doubling of Multiple Myeloma Incidence
MT Newswires -Shutterstock GSK (GSK.L) received approval from China’s National Medical Products Administration for Blenrep, providing a new…
GSK and the pan-Canadian Pharmaceutical Alliance (pCPA) initiate negotiations for Blenrep for the treatment of relapsed or refractory multiple myeloma
MISSISSAUGA, ON, May 20, 2026 /CNW/ – GSK is pleased to welcome the start of negotiations with the pCPA…